Ophthalmology Times Staff Reports

1245 S UTICA AVE

Articles

Tie2 activator augments anti-VEGF for DME

May 04, 2016

Results from TIME-2, a phase IIA study, support further development of combination treatment with subcutaneous injection of the Tie2 activator, AKB-9778 (Aerpio Therapeutics), plus intravitreous (IVT) anti-VEGF injection for diabetic macular edema.